Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 14/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17767008 | 0.85 | SMN1; SMN2 (0.81) | GPR139POLBSMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17767162 | 0.84 | GPR139 (0.82) | GPR139POLBSMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17769135 | 0.82 | GPR139 (0.77) | GPR139POLBSMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17767112 | 0.80 | GPR139 (0.81) | GPR139POLBSMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17767010 | 0.80 | GPR139 (1.00) | GPR139POLBSMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17766979 | 0.80 | GPR139 (0.74) | GPR139POLBSMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17767192 | 0.80 | GPR139 (0.82) | GPR139POLBSMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17767026 | 0.79 | GPR139 (0.64) | GPR139POLBSMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17766910 | 0.79 | GPR139 (0.80) | GPR139POLBSMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17767229 | 0.79 | GPR139 (0.80) | GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173161-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| EP-3536324-B1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICALS CO (JP) | 2021-10-06 | — | — | EP | disclosed |
| US-20200129518-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2020-04-30 | — | — | US | disclosed |
| US-10561662-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-18 | — | — | US | disclosed |
| EP-3536324-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | Takeda Pharmaceutical Company Limited (JP) | 2019-09-11 | — | — | EP | disclosed |
| EP-3221298-B1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE DERIVATIVES AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICALS CO (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-20190070187-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2019-03-07 | — | — | US | disclosed |
| US-10159677-B2 | 4-OXO-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-12-25 | — | — | US | disclosed |
| US-20170348319-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3221298-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | Takeda Pharmaceutical Company Limited (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-9770450-B2 | 4-OXO-3,4-dihydro-1,2,3-benzotriazine as modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170095480-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2017-04-06 | — | — | US | disclosed |
| US-9556130-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160145218-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | TAKEDA CALIFORNIA, INC. | 2016-05-26 | — | — | US | disclosed |
| WO-2016081736-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070187-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885POLB 4677/4885SMN1; SMN2 3239/4885 |
| US-20200129518-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885POLB 4677/4885SMN1; SMN2 3239/4885 |
| US-20170095480-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE AS MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885POLB 4749/4885SMN1; SMN2 3466/4885 |
| US-20160145218-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885POLB 4677/4885SMN1; SMN2 3239/4885 |
| US-10561662-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885POLB 4677/4885SMN1; SMN2 3239/4885 |
| US-10159677-B2 | 4-OXO-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885POLB 4677/4885SMN1; SMN2 3239/4885 |
| US-20170348319-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885POLB 4677/4885SMN1; SMN2 3239/4885 |
| US-11173161-B2 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | GPR139, GPR3, GPR84 | GPR139 1/4885POLB 4677/4885SMN1; SMN2 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.